[Form 4/A] TENAX THERAPEUTICS, INC. Amended Insider Trading Activity

Rhea-AI Filing Summary

Tenax Therapeutics, Inc. (TENX) director reported open-market purchases of common stock and corrected how those shares are reported. On 11/17/2025, an indirect account bought 93 shares at $7.15 per share, and on 11/18/2025 it bought 1,900 shares at a weighted average price of $7.5157, for a total of 1,993 shares held through Meadowlark Management, LLC. This amended Form 4 changes the ownership form for those 1,993 shares from direct to indirect, clarifying that the director disclaims beneficial ownership beyond her economic interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Almenoff June Sherie

(Last) (First) (Middle)

101 GLEN LENNOX DRIVE, SUITE 300

(Street)

CHAPEL HILL NC 27517

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TENAX THERAPEUTICS, INC. [ TENX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
11/19/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/17/2025		P		93	A	$7.15	93	I	By Meadowlark Management, LLC(1)
Common Stock	11/18/2025		P		1,900	A	$7.5157(2)	1,993	I	By Meadowlark Management, LLC(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.

2. This transaction was executed in multiple trades at prices ranging from $7.45 to $7.70. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

Remarks:

This amendment is being filed to correct the ownership form of the 1,993 shares acquired, which was inadvertently reported on the original filing as direct. Columns 6 and 7 have been adjusted to reflect this correction.

	/s/ S. Halle Vakani, as Attorney-in-Fact	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Tenax Therapeutics (TENX) director report in this Form 4/A?

The director reported open-market purchases of 1,993 shares of Tenax Therapeutics common stock made on 11/17/2025 and 11/18/2025, held through Meadowlark Management, LLC.

Why was this Tenax Therapeutics (TENX) Form 4 amended?

The amendment corrects the ownership form of the 1,993 shares, which were originally reported as owned directly but are now shown as owned indirectly through Meadowlark Management, LLC.

At what prices were the TENX shares purchased in this filing?

The filing shows 93 shares bought at $7.15 per share on 11/17/2025 and 1,900 shares at a weighted average price of $7.5157 on 11/18/2025.

How many Tenax Therapeutics shares does the director report owning after these transactions?

After the reported transactions, the director reports 1,993 shares of Tenax Therapeutics common stock held indirectly through Meadowlark Management, LLC.

What does it mean that the TENX shares are held indirectly through Meadowlark Management, LLC?

Indirect ownership through Meadowlark Management, LLC means the shares are held by that entity, and the director reports them as beneficially owned but disclaims ownership beyond her pecuniary interest.

What is the director’s relationship to Tenax Therapeutics (TENX) noted in the Form 4/A?

The filing identifies the reporting person’s relationship to Tenax Therapeutics as a Director of the company.